Words of wisdom. Re: phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration- resistant prostate cancer commonly remains hormone driven.

Find Full text
Thumbnail
Fulltext:
69394schalken.pdf
Embargo:
until further notice
Size:
113.2Kb
Format:
PDF
Description:
Publisher’s version
Publication year
2008
Author(s)
Schalken, J.A.
Source
European Urology, 54, 6, (2008), pp. 1438-9
ISSN
DOI
Publication type
Article / Letter to editor
Please use this identifier to cite or link to this item: https://hdl.handle.net/2066/69394   https://hdl.handle.net/2066/69394
Display more details

Upload full text

Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.